942271-61-6

Basic information

• Product Name: tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate
• Synonyms: tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate
• CAS NO: 942271-61-6
• Molecular Formula: C₁₆H₂₃N₃O₄
• Molecular Weight: 321.37152
• Mol File: 942271-61-6.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 449.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.181±0.06 g/cm3(Predicted)
• PKA: 7.39±0.42(Predicted)
• CAS DataBase Reference: tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate(942271-61-6)
• EPA Substance Registry System: tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate(942271-61-6)

Safety Data

• Hazardous Substances Data: 942271-61-6(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate is a chemical compound with the molecular formula C16H24N4O4. It is a nitrobenzoate derivative that contains a tert-butyl group, a methylpiperazine group, and a nitro group. tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate is commonly used in the field of medicinal chemistry and pharmaceutical research as a building block in the synthesis of various biologically active compounds. Its structure and properties make it useful for studying drug-receptor interactions and developing new therapeutic agents. Additionally, it is important to handle and store this chemical with care and follow appropriate safety protocols due to its potential hazards and reactivity.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 942271-60-5 tert-butyl 4-fluoro-2-nitrobenzoate 
• 394-01-4 4-fluoro-2-nitrobenzoic acid 

Downstream Products

• 942271-64-9 4-(4-methyl-piperazin-1-yl)-2-nitro-benzoic acid hydrochloride 
• 1034975-35-3 tert‐butyl 2‐amino‐4‐(4‐methylpiperazin‐1‐yl)benzoate 
• 1392150-68-3 tert-butyl 2-((4,4-difluorocyclohexyl)amino)-4-(4-methylpiperazin-1-yl)benzoate 
• 1392150-69-4 tert-butyl 2-(N-(4,4-difluorocyclohexyl)-2,2,2-trifluoroacetamido)-4-(4-methylpiperazin-1-yl)benzoate 
• 1034975-40-0 tert-butyl 4-(4-methylpiperazin-1-yl)-2-(tetrahydropyran-4-ylamino)benzoate 
• 942471-28-5 tert-butyl 2-[2-methoxyethyl-(2,2,2-trifluoroacetyl)amino]-4-(4-methylpiperazin-1-yl)benzoate 
• 1034975-62-6 4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoic acid trifluoroacetic acid salt 
• 1034975-72-8 2-[2-methoxyethyl-(2,2,2-trifluoroacetyl)amino]-4-(4-methylpiperazin-4-ium-1-yl)benzoic acid 2,2,2-trifluoroacetate 
• 1034976-52-7 4-(4-methylpiperazin-1-yl)-2-[(tetrahydropyran-4-yl)-(2,2,2-trifluoroacetyl)amino]benzoyl chloride 
• 1108745-38-5 N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide 
• 1108743-60-7 N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide 

Relevant articles and documents

Indazole compound for inhibiting kinase activity as well as composition and application thereof

The invention relates to an indazole compound for inhibiting kinase activity and relates to preparation and application of the indazole compound. Specifically, the invention discloses the indazole compound shown as a formula (I), or crystal forms, prodrugs, pharmaceutically acceptable salts, stereoisomers, tautomers, solvates or pharmaceutical compositions of hydrates of the indazole compound. Thecompound and the composition containing the compound, provided by the invention, have excellent inhibition performance on kinase protein, and also have better pharmacokinetics parameter characteristics at the same time; the medicine concentration of the compound in animals can be improved and the curative effect and safety of the medicine are improved. The formula (I) is shown in the description.

Derivatives of azaindoles or diazaindoles for treating pain

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK

The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.